.png){kind=logo}
Stock image for illustration purposes only - book cover, edition or condition may vary.
Novel Developments in Stem Cell Mobilization
. Ed(S): Fruehauf, Stefan; Zeller, Jens; Calandra, Gary B.
€ 197.20
FREE Delivery in Ireland
Description for Novel Developments in Stem Cell Mobilization
Hardback. This book reports on CXCR4 antagonists, an exciting new class of compounds that aid in use of stem cells for treatment of leukemia and other cancers. Includes coverage of plerixafor, now approved for stem cell mobilization of lymphoma and myeloma patients. Editor(s): Fruehauf, Stefan; Zeller, Jens; Calandra, Gary B. Num Pages: 512 pages, biography. BIC Classification: MJCL; MMG. Category: (P) Professional & Vocational. Dimension: 237 x 163 x 34. Weight in Grams: 942.
Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized ... Read more
Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized ... Read more
Product Details
Format
Hardback
Publication date
2012
Publisher
Springer-Verlag New York Inc. United States
Number of pages
512
Condition
New
Number of Pages
498
Place of Publication
New York, NY, United States
ISBN
9781461419594
SKU
V9781461419594
Shipping Time
Usually ships in 15 to 20 working days
Ref
99-15
Reviews for Novel Developments in Stem Cell Mobilization